Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (NASDAQ: EXAS) is frequently in the news as a leading provider of cancer screening and diagnostic tests. Company announcements highlight developments across stool-based colorectal cancer screening, multi-cancer early detection, liver cancer surveillance, and precision oncology genomics. News coverage often reflects new clinical data, product launches, collaborations, and corporate transactions that shape the company’s role in cancer diagnostics.
Investors and clinicians following EXAS news can expect updates on the performance and adoption of the Cologuard and Cologuard Plus colorectal cancer screening tests, including real‑world adherence data and modeling studies that examine benefit‑to‑burden trade‑offs. Exact Sciences also reports on progress with its Cancerguard multi‑cancer early detection blood test, including study results from large prospective trials designed to support broader clinical use.
Another recurring theme in Exact Sciences news is the expansion of its precision oncology and surveillance portfolio. Releases describe pivotal and prospective studies of the Oncoguard Liver blood test for hepatocellular carcinoma surveillance, the Oncodetect molecular residual disease test in high‑risk breast cancer and other solid tumors, and the OncoExTra comprehensive genomic profiling assay for advanced cancers. These updates often come from major scientific meetings and include details on sensitivity, specificity, and prognostic performance.
Corporate and financial news items for EXAS include quarterly earnings releases, updated revenue and adjusted EBITDA guidance, participation in investor conferences, and strategic agreements such as the collaboration and license arrangement with Freenome for blood‑based colorectal cancer screening tests. A notable development disclosed in both press releases and SEC filings is the definitive agreement under which Abbott Laboratories plans to acquire Exact Sciences, subject to stockholder and regulatory approvals and other customary conditions.
This news page aggregates such announcements, offering a single place to review Exact Sciences’ latest clinical, product, financial, and transaction-related updates over time.
Exact Sciences (NASDAQ: EXAS) will present four AACR 2026 posters and an oral presentation April 17–22, 2026, in San Diego highlighting new molecular residual disease (MRD) and multi-cancer early detection (MCED) data.
Key findings: post-neoadjuvant tumor-informed ctDNA (Oncodetect) strongly associated with non-pCR and distant recurrence in early TNBC; comprehensive tumor profiling found actionable alterations in ~50% of breast and colorectal samples; an optimized methylation–protein MCED classifier (MP V2) showed improved early-stage sensitivity while maintaining high specificity; methylation and protein biomarkers contributed complementary signals.
Exact Sciences (NASDAQ: EXAS) was named a 2026 Gallup Exceptional Workplace Award winner for the third consecutive year on March 4, 2026. The award recognizes highly engaged workplace cultures; Gallup cited employee engagement, connection to mission, and strong performance during change based on its global meta-analysis.
The company highlighted its workforce commitment and invited applicants to view job openings on its careers site.
Privia Health (NASDAQ:PRVA), Amalgam Rx, and Exact Sciences (NASDAQ:EXAS) report a Privia-led colorectal cancer screening program that reached an 84% screening rate in 2024, above the 80% national goal. The EHR-integrated, automated outreach program engaged >42,000 patients (scaled to >100,000), processed ~23,000 orders within 48 hours, and found a 10% positivity rate identifying >550 patients needing follow-up.
The program used Cologuard as a noninvasive first-line option and embedded ordering, results, and follow-up into athenaClinicals to support value-based care and eCQM readiness.
Exact Sciences (NASDAQ: EXAS) stockholders voted to approve the proposed acquisition by Abbott (NYSE: ABT) at a special meeting held February 20, 2026. Preliminary results showed >99% of votes cast, representing ~67% of outstanding shares as of the January 9, 2026 record date, voted in favor.
Subject to satisfaction or waiver of remaining closing conditions, the transaction is expected to close before the end of the second calendar quarter of 2026. According to the company, each Exact Sciences share will receive $105.00 in cash upon completion, without interest and subject to applicable withholding taxes. Final voting results will be reported on Form 8-K filed with the SEC.
Exact Sciences (Nasdaq: EXAS) reported record results: Q4 2025 revenue $878M (+23%) and FY2025 revenue $3.25B (+18%). Operating cash flow was $491M, free cash flow $357M, net loss $208M, and adjusted EBITDA $400M. The company announced clinical wins, a U.S. license from Freenome, and a pending merger with Abbott with a stockholder vote on Feb 20, 2026 and targeted close in Q2 2026 subject to approvals.
Exact Sciences (NASDAQ: EXAS) hailed passage of federal legislation creating a Medicare coverage pathway for multi-cancer early detection (MCED) tests on February 3, 2026. The law links coverage to FDA approval and subsequent CMS implementation, aiming to expand access for Medicare beneficiaries.
Exact Sciences noted its Cancerguard test is under continued clinical evaluation and cited modeling that suggests adding MCED to standard screening could reduce stage IV diagnoses by 45%.
Exact Sciences (Nasdaq: EXAS) said its Oncotype DX Breast Recurrence Score test has been used by more than 2 million patients worldwide as of February 3, 2026, guiding adjuvant therapy decisions for early-stage HR+, HER2- breast cancer.
The company reports an estimated 1.6 million patients avoided potentially unnecessary chemotherapy and U.S. lifetime savings of about $10,000 per patient, citing validation across diverse populations and a Category 1A NCCN recommendation.
Exact Sciences (NASDAQ: EXAS) presented first clinical results for the Oncodetect® MRD test in early triple-negative breast cancer (TNBC) at SABCS on December 11, 2025. In a 147-patient substudy of NSABP B-59, post-surgery ctDNA (MRD) positivity was associated with ~30-fold higher risk of distant recurrence versus MRD-negative patients, while 95% of MRD-negative patients remained distant recurrence-free at 3 years. Neoadjuvant therapy reduced ctDNA positivity from 95% pre-treatment to 9% post-treatment. Median follow-up was 37 months. The groups plan journal submission and a MolDx filing for Medicare coverage.
Exact Sciences (Nasdaq: EXAS) will present 10 abstracts at the 2025 San Antonio Breast Cancer Symposium, Dec 9-12, highlighting clinical validation and real‑world data across its Precision Oncology portfolio.
Key items include the first clinical validation of the Oncodetect test in triple‑negative breast cancer with highly sensitive MRD detection, a large ongoing NSABP B‑64 trial enrolling >1,800 patients with readouts starting in 2027, and multiple Oncotype DX studies showing improved outcomes, guideline‑concordant use across racial and ethnic groups, and an estimated >€60M chemotherapy cost savings in Ireland.
Abbott (NYSE: ABT) agreed to acquire Exact Sciences (NASDAQ: EXAS) for $105 per share, implying approximately $21 billion equity value and an estimated $23 billion enterprise value; Abbott will absorb about $1.8 billion of Exact Sciences net debt. Exact Sciences is projected to generate more than $3 billion in revenue this year with high‑teens organic growth and brings leading assets including Cologuard, Oncotype DX, Oncodetect and Cancerguard. Abbott expects the deal to be immediately accretive to revenue growth and gross margin. Closing is expected in Q2 2026, subject to shareholder and regulatory approvals.